SCHEMBL14735527

SCHEMBL14735527

COc1cc(O)ccc1[N+](=O)[O-].COc1cc(OCCN2CCOCC2)ccc1N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.60
ALDH1A1 P00352 6/20 0.60
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
CHEK1 O14757 1/20 0.49
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
HTT P42858 1/20 0.48
ESR2 Q92731 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
TP53 P04637 1/20 0.44
PPARG P37231 1/20 0.44
LMNA P02545 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375580 0.88 KDM4E (0.68) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL29788583 0.88 KDM4E (0.68) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5768844 0.83 KDM4E (0.55) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL375708 0.83 ALDH1A1 (0.58) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL29788588 0.83 ALDH1A1 (0.58) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL375129 0.80 KDM4E (0.65) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL30511318 0.80 KDM4E (0.64) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3381012 0.80 KDM4E (0.64) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3647469 0.80 SIRT6 (0.51) KDM4EALDH1A1KMT2AMEN1HTT
SCHEMBL1964818 0.79 KDM4E (0.66) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275413-B1 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2013-03-06 EP disclosed